| Literature DB >> 30583601 |
Wei Zhang1, Nan Zheng2, Lu Chen3, Luyao Xie4, Mingshu Cui5, Sanming Li6, Lu Xu7.
Abstract
The use of mesoporous silica nanoparticles (MSNs) in the field of oral drug delivery has recently attracted greater attention. However, there is still limited knowledge about how the shape of MSNs affects drug delivery capacity. In our study, we fabricated mesoporous silica nanorods (MSNRs) to study the shape effects of MSNs on oral delivery. MSNRs were characterized by transmission electron microscopy (TEM), nitrogen adsorption/desorption, Fourier transform infrared spectroscopy (FTIR), and small-angle X-ray diffraction (small-angle XRD). Indomethacin (IMC), a non-steroidal anti-inflammatory agent, was loaded into MSNRs as model drug, and the drug-loaded MSNRs resulted in an excellent dissolution-enhancing effect. The cytotoxicity and in vivo pharmacokinetic studies indicated that MSNRs can be applied as a safe and efficient candidate for the delivery of insoluble drugs. The use of MSNs with a rod-like shape, as a drug delivery carrier, will extend the pharmaceutical applications of silica materials.Entities:
Keywords: drug delivery; indomethacin; mesoporous silica nanoparticles; shape effect
Year: 2018 PMID: 30583601 PMCID: PMC6359657 DOI: 10.3390/pharmaceutics11010004
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Scheme 1Preparation of mesoporous silica nanospheres (MSNSs) and mesoporous silica nanorods (MSNRs).
Figure 1TEM images of mesoporous silica nanoparticles (MSNs).
Figure 2Small-angle XRD patterns of MSNs (a); nitrogen adsorption/desorption isotherm (b); and pore size distribution curve (c) of MSNs.
Detailed textural parameters of MSNs by N2 adsorption measurements.
| Sample | |||
|---|---|---|---|
| MSNSs | 907.20 | 0.82 | 4.7 |
| MSNRs | 1074.22 | 0.96 | 5.8 |
Figure 3FTIR spectra (a) and XRD patterns (b) of IMC, IMC-MSNRs, IMC-MSNSs, MSNRs, and MSNSs.
Figure 4Release profile of IMC-MSNRs, IMC-MSNSs, and IMC. Statistical significance is represented by ** p < 0.01.
Release rate constants and r2 coefficients obtained from release data fitting analyses based on several kinetic equations.
| Kinetic Equations | IMC | IMC-MSNSs | IMC-MSNRs |
|---|---|---|---|
| Zero-order | |||
| First-order | |||
| Quadratic | |||
| Higuchi | |||
| Hixson-Crowell | |||
| Weibull | |||
| Baker-Lonsdale | 1.5 × [1 − (1 − | 1.5 × [1 − (1 − | 1.5 × [1 − (1 − |
| 1.5 × [1 − (1 − | |||
| Peppas-Sahlin | |||
| Korsmeyer-Peppas | |||
Figure 5Viability of Caco-2 cells after incubation with naked MSNRs or MSNSs for 24 h. Control group: DMEM medium without serum (mean ± SD, n = 3).
Pharmacokinetic parameters of IMC after oral administration of different IMC formulations at a dose of 40 mg/kg to rats (mean ± SD, n = 3).
| Formulation | AUC0→t (mg∙h/L) | Frel (%) | ||
|---|---|---|---|---|
| IMC | 234.2 ± 16.0 | 4.7 | 3240 ± 117 | - |
| IMC-MSNSs | 417.4 ± 36.3 | 3.7 | 5398 ± 746 | 167 |
| IMC-MSNRs | 928.0 ± 24.8 | 2.3 | 7275 ± 608 | 225 |
Figure 6Plasma concentration vs. time profile of different IMC formulations after oral administration (mean ± SD, n = 3). Statistical significance is represented by * p < 0.05, ** p < 0.01.